Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 108Unknown 28Terminated 26Recruiting 22Active not recruiting 8Withdrawn 6Not yet recruiting 4Suspended 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Neoplasms 35Breast Neoplasms 30Prostatic Neoplasms 22Leukemia, Myeloid, Acute 20Colorectal Neoplasms 20Melanoma 17Pancreatic Neoplasms 16Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 15Lung Neoplasms 13Brain Neoplasms 13Glioma 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Carcinoma, Hepatocellular 11Ovarian Neoplasms 10Multiple Myeloma 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Carcinoma, Renal Cell 8Leukemia 7Sarcoma 6Rectal Neoplasms 6Hematologic Neoplasms 6Esophageal Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5

Interventions

tivozanib 1atezolizumab 1Protein Subunit Vaccines 1LY6K protein, human 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Interventional × Bile Duct Neoplasms × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00624182 2015-06-23

Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

Akita University Hospital

Phase 1 Suspended
9 enrolled
Gastrointestinal

Bile Duct Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡